CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

Sector

Pharmaceuticals

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	2.65M 2.3M 2.14M 1.97M 3.71M 253M 3.77M 25.25M 9.91M 126M 9.94M 9.72M 422M	P/E 2024	-1.11x	P/E 2025	-0.33x
Enterprise Value	24.5M 21.3M 19.82M 18.2M 34.37M 2.34B 34.9M 234M 91.71M 1.16B 92.02M 90M 3.9B	EV / Sales 2024	1.75x	EV / Sales 2025	1.9x
Free-Float	53.62%	Yield 2024 *	-	Yield 2025	-

06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-15	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
04-21	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP	CI
04-21	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026	CI
03-03	CASI Pharmaceuticals, Inc. Announces CEO Changes	CI
03-03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026	CI

Manager	Title	Age	Since
David Cory CEO	Chief Executive Officer	62	21/07/2025
Kun Qian DFI	Director of Finance/CFO	44	16/05/2025
Chun Hua Wang COO	Chief Operating Officer	54	01/01/2017

Director	Title	Age	Since
Yue Wu BRD	Director/Board Member	62	01/04/2013
Zhen Bo Su BRD	Director/Board Member	50	21/03/2023
Thomas Folinsbee BRD	Director/Board Member	59	21/03/2023

ENTREMED Stock Nasdaq

Stocks

Pharmaceuticals

Valuation: ENTREMED

Latest news : ENTREMED

Press Releases: ENTREMED

Managers and Directors: ENTREMED

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-0.53%	-3.95%	+50.70%	+152.78%	1,024B
JOHNSON & JOHNSON	+0.21%	-2.68%	+53.20%	+50.87%	618B
ABBVIE INC.	-2.51%	-3.25%	+28.54%	+67.99%	443B
ROCHE HOLDING AG	+0.06%	-0.42%	+37.53%	+31.06%	349B
ASTRAZENECA PLC	-0.69%	-0.30%	+13.76%	+13.84%	264B
NOVO NORDISK A/S	-7.37%	-4.40%	-0.74%	-43.66%	209B
AMGEN INC.	-0.64%	+2.43%	+29.74%	+67.16%	208B
GILEAD SCIENCES, INC.	-0.82%	+0.70%	+15.05%	+72.05%	162B
PFIZER INC.	+0.40%	+1.92%	+6.47%	-29.25%	143B
Average	-1.32%	-1.11%	+26.03%	+42.54%	379.88B
Weighted average by Cap.	-1.00%	-2.16%	+36.14%	+71.63%

	2024	2025
Net sales	28.54M 24.81M 23.09M 21.2M 40.03M 2.72B 40.65M 272M 107M 1.36B 107M 105M 4.55B	20.71M 18M 16.76M 15.39M 29.06M 1.98B 29.51M 198M 77.53M 984M 77.79M 76.08M 3.3B
Net income	-39.26M -34.13M -31.76M -29.16M -55.07M -3.75B -55.93M -374M -147M -1.87B -147M -144M -6.26B	-48.06M -41.78M -38.89M -35.7M -67.42M -4.59B -68.46M -458M -180M -2.28B -180M -177M -7.66B
Net Debt	6.05M 5.26M 4.9M 4.49M 8.49M 578M 8.62M 57.7M 22.65M 288M 22.72M 22.22M 964M	21.85M 19M 17.68M 16.23M 30.66M 2.09B 31.13M 208M 81.8M 1.04B 82.07M 80.27M 3.48B

End-of-day quote Nasdaq Other stock markets
- ^USD	-